BioCentury
ARTICLE | Clinical News

AutoSynVax: Ph I started

April 7, 2017 3:30 PM UTC

Agenus began an open-label, U.S. Phase I trial to evaluate 240 µg subcutaneous AutoSynVax plus the company's QS-21 Stimulon adjuvant given every 2 weeks for up to 1 year in about 20 patients....

BCIQ Company Profiles

Agenus Inc.

BCIQ Target Profiles

Heat shock protein 70 (Hsp70)